AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 2 - (NewsRx.com & NewsRx.net) -- Researchers describe complement function in monoclonal-antibody-mediated cancer immunotherapy in a recent issue of Trends in Immunology.
"Complement activation by monoclonal antibodies can cause direct tumor cell lysis or enhance antibody-dependent cell-mediated cytotoxicity. However, tumor cells are protected from complement-mediated injury by membrane-bound complement regulatory proteins [mCRP) that are often expressed at elevated levels on tumor cells. Recent studies indicate that blocking or overwhelming the function of tumor cell mCRP might substantially improve the efficacy of monoclonal antibody (mAb) immunotherapy," scientists in the Netherlands and United States report.
"In addition, the use of beta-glucan as an adjuvant for mAb immunotherapy enables iC3b deposited on tumor cells by mAbs to activate complement receptor 3 (CR3) on effector cells, thus inducing CR3-dependent cellular cytotoxicity," stated Kyra A. Gelderman and collaborators at Leiden University in the Netherlands and the ...
Source: HighBeam Research, Complement function in antibody-mediated cancer immunotherapy...